李氏大藥廠控股有限公司（簡稱：李氏大藥廠或集團）是一家以研究為驅動、市場為導向的生物醫藥公司，在中國製藥行業已有25餘年的經驗。李氏大藥廠於2002年7月在香港聯合交易所（「港交所」）創業板上市，並於2010年5月成功轉至港交所主板上市。
發展
集團成立於1994年，主要業務集中於自主研發、生產、銷售生物藥物產品，產品專注於心血管和傳染病的領域。自2002年在港交所創業板上市以來，集團業務經營範圍不斷擴大。於2000年代期間，集團與歐美等國家藥廠合作將產品投入內地市場，並將業務擴展到兒科、婦產科、罕見病、皮膚科、泌尿科、腫瘤和眼科等疾病治療領域。
更多詳情，可瀏覽：https://www.leespharm.com/
Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in Hong Kong and China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives.
The Company has established extensive partnerships with over 20 international companies and currently markets 23 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics and urology, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies.
Lee’s Pharm has also involved in the business in ophthalmology through its investment in Zhaoke Ophthalmology Limited, an associated company of the group.
